Biosimilar
European Commission approves Opuviz as aflibercept biosimilar
The European Commission has approved Opuviz 40 mg/mL solution, a biosimilar referencing Eylea, according to a press release from Samsung Bioepis and Biogen.
Practice-level policies ‘likely key drivers’ of infliximab biosimilar uptake
WASHINGTON — Biosimilar infliximab use is significantly more common among new users vs. those who started with the originator, and particularly less likely among Medicare beneficiaries, according to data presented at ACR Convergence 2024.
‘No meaningful difference’: Zymfentra monotherapy as effective as combined therapy for IBD
PHILADELPHIA — Zymfentra as monotherapy was no more effective when combined with immunosuppressants for maintenance therapy in patients with Crohn’s disease or ulcerative colitis, according to post-hoc analysis presented here.
EHR can help automate biosimilar selection, streamline prior authorization
An electronic health record tool has demonstrated the potential to automate the selection of biosimilars.
Biosimilar retention not impacted by comorbidities in inflammatory RMDs
The presence of comorbidities with inflammatory rheumatic musculoskeletal diseases made little difference in biosimilar retention after a non-medical switch, according to data published in Arthritis Research & Therapy.
FDA approves Otulfi as fourth Stelara biosimilar for chronic inflammatory diseases
The FDA has approved subcutaneous and IV formulations of the Stelara biosimilar Otulfi for Crohn’s disease, ulcerative colitis and all other indications approved for the reference product, according to a press release from Fresenius Kabi.
Healio Minute Podcast, Rheumatology/Psoriatic Arthritis Edition: Top Headlines - Week of September 23, 2024
In this edition, blue-collar workers more likely to miss work or quit due to psoriatic arthritis, infliximab biosimilar increase after release of a third option and more.
Infliximab biosimilar uptake rapidly increased only after release of a third option
Infliximab biosimilar uptake increased by no more than just 5% annually following the release of its first two biosimilars, but then shot up by 13% to 16% for most patients after a third option emerged, according to data.
PBMs vs. patients: The hidden battle for affordable biosimilars
Biosimilar medications — drugs developed to be very similar, but not identical, to an FDA-approved biologic — were intended to play a vital role in increasing affordable options for patients struggling with a range of chronic conditions.
ACR praises FDA plan to end switching study requirement for interchangeable biosimilars
The American College of Rheumatology has applauded an FDA proposal to streamline the approval of interchangeable biosimilars, removing requirements for switching studies to determine their interchangeability with reference products.